Option chain shows key data for TransAtlantic Capital's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for TransAtlantic Capital.

TransAtlantic Capital (OTC:TACI) Stock, Option Chain

TransAtlantic Capital Inc is engaged in emerging diversified investment vehicle focused on three key industries. -Housing, Maritime Shipping, and Agriculture encompassing.

Cannabis

News

Penny Stocks

Movers & Shakers

Small Cap

Markets

General

ACRDF

AGFY

CERAF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

SAMA

TACI

THCX

CLVR

CSE:MCUR

CSE:ACRG

Clever Leaves Appoints Hank Hague As CFO



Cannabis Movers &amp; Shakers: Clever Leaves, Agrify, Mind Cure, NXT Water, Acreage, Parallel, Transatlantic Capital

Intraday Update

Movers

Trading Ideas

ABEO

ADAP

ADTR

ADXS

AETUF

AGHI

ALKS

AMGDF

ARGGY

ASMB

ASNA

Alterity Therapeutics Limited - American Depositary Shares

ATHE

ATRA

AVRI

AXAS

BCEFF

BCEL

BDIC

BEWFF

BGFV

BIEI

BJCHY

BJRI

BKRIF

BKUT

BLIN

BMYMP

BNDSF

BNDSY

BNIKF

BOTH

BRSWQ

CAIXY

CARB

CBGPY

CBIS

CDEV

CEIX

CESDF

CGLDF

CHKDG

CINR

CLUB

CLVS

CMSQY

CNKEF

COIHF

CORV

China Shenhua Energy Unsponsored representing A shares

CSUAY

CTRA

CUAEF

Changyou Limited American Depositary Share

CYOU

CYTX

DBLVF

DCTH

DKGH

DLTH

DMIFF

DNJR

DPDW

DPGYF

DVAX

ETRN

EVAHF

EXPR

FCUUF

FELP

FNJN

FOMX

FPLSF

FRAC

FURGF

FVANF

GARB

GNFT

GPOR

GTHR

Stocks That Managed to Breach 52-Week Lows Friday

TRANSATLANTIC CAPITAL INC by TransAtlantic Capital Inc.

TransAtlantic Capital Inc

Needham analyst John Todaro maintains Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) with a Buy and raises the price target from $11 to $16.

Price Target

Analyst Ratings

RIOT

Needham Maintains Buy on Riot Platforms, Raises Price Target to $16

On Tuesday, January 21st, U.S. markets closed mixed, with the S&amp;P 500 and Dow reaching month-highs as investors welcomed a restrained approach to tariffs in President Trump&#8217;s initial actions. While concerns about trade policy persist, markets were buoyed by hopes for a more strategic, negotiable approach to tariffs.
Most sectors on the S&amp;P 500 closed higher on Tuesday, with notable gains in industrials, real estate, and health care, reflecting broad market strength. However, energy stocks diverged from the overall positive trend, ending the session lower amid sector-specific pressures.
The Dow Jones Industrial Average was up 1.24% and closed at 44,025.81, the S&amp;P 500 closed higher by 0.88% at 6,049.24, and the Nasdaq Composite rose 0.64% to finish at 19,756.78.
Aisa Markets Today
<ul>
<li>On Wednesday, Japan&#8217;s Nikkei 225 closed higher by 1.58% at 39,615.50, led by gains in the Precision Instruments, Manufacturing and Textile sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 gained 0.33%, ending the session at 8,429.80, led by gains in the IT, Gold, and Industrials sectors.</li>
<li>India&#8217;s Nifty 50 closed higher by 0.58% at 23,159.30, while the Nifty 500 declined 0.15%, closing at 21,400.80.</li>
<li>China&#8217;s Shanghai Composite declined 0.89% and closed at 3,213.62, and the Shenzhen CSI 300 slid 0.93%, finishing the day at 3,797.02.</li>
<li>Hong Kong Hang Seng closed the session lower by 1.63% at 19,778.77.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 was up 0.83%.</li>
<li>Germany&#8217;s DAX rose 1.13%.</li>
<li>France&#8217;s CAC rose 0.77%.</li>
<li>U.K.&#8217;s FTSE index 100 traded higher by 0.24%.</li>
<li>European stocks rose modestly Wednesday amid cautious sentiment on trade threats from Trump&#8217;s administration. The focus remained on Davos, ECB rate cuts, EasyJet&#8217;s recovery, AI investments, and oil price drops due to U.S. output plans.</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 0.58% at $76.27/bbl, and Brent was up 0.49% at $79.70/bbl.</li>
<li>Oil prices fell further Wednesday as markets reacted to Trump&#8217;s energy emergency declaration, plans to maximize U.S. production, and potential tariffs on Canada and Mexico amid mixed global demand signals.</li>
<li>Natural Gas gained 0.53% to $3.776.</li>
<li>Gold was trading higher by 0.49% at $2,772.71, Silver was up 0.42% to $31.628, and Copper fell 0.24% to $4.3305.</li>
<li>Gold prices rose to an 11-week high amid safe-haven demand driven by tariff uncertainties under Trump&#8217;s administration, while copper prices dropped on weaker demand prospects and stronger dollar concerns.</li>
</ul>
U.S. Futures at 05:30 AM ET
Dow futures were up 0.13%, S&amp;P 500 futures rose 0.40% and Nasdaq 100 futures gained 0.78%.
Forex at 05:30 AM ET
<ul>
<li>The U.S. Dollar Index declined 0.14% to 107.80, USD/JPY gained 0.14% to 155.71, and USD/AUD declined 0.26% to 1.6897.</li>
<li>The dollar hovered near two-week lows amid uncertainty over Trump&#8217;s tariff plans, with mixed currency movements reflecting cautious sentiment.</li>
</ul>
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Mixed, Europe Up As Trump's Tariff Plans Sparks Market Caution; Gold Hits 11-Week High - Global Markets Today While US Slept

Telsey Advisory Group analyst Dana Telsey maintains Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) with a Outperform and maintains $26 price target.

LEVI

Telsey Advisory Group Maintains Outperform on Levi Strauss, Maintains $26 Price Target

JFBR

Jeffs' Brands announced that it has issued a non- recourse convertible promissory note in the principal amount of $2,850,000 to an institutional investor

WIIM

GE Vernova shares are trading lower after the company reported worse-than-expected Q4 EPS and revenue.

Telsey Advisory Group analyst Dana Telsey maintains VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Market Perform and maintains $21 price target.

Telsey Advisory Group Maintains Market Perform on VF, Maintains $21 Price Target

Needham analyst Gil Blum initiates coverage on Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) with a Buy rating and announces Price Target of $9.

Initiation

ABSI

Needham Initiates Coverage On Absci with Buy Rating, Announces Price Target of $9

Guidance

Textron Sees FY25 Adj. EPS $6.00-$6.20 vs $6.42 Est.

Potter will also join the Company's Board of Directors. Potter will succeed Eric J. Lindberg, Jr., who has served as Interim President and Chief Executive Officer since October 2024.&nbsp;

Management

Grocery Outlet Holding Appoints Jason Potter As President And CEO, Effective February 3, 2025

Earnings

Earnings Misses

Textron Q4 2024 Adj. EPS $1.34, Inline, Sales $3.613B Miss $3.810B Estimate

Guidance:
GE Vernova is reaffirming its 2025 financial guidance of revenue of $36-$37 billion, high-single digits adjusted EBITDA margin&#x2A;, free cash flow&#x2A; of $2.0-$2.5 billion, and segment guidance of:&nbsp;
•Power: Mid-single digit organic revenue&#x2A; growth and 13%-14% segment EBITDA margin.
•Wind: Organic revenue&#x2A; down mid-single digits and $200-$400 million of segment EBITDA losses.
•Electrification: Mid-to-high-teens organic revenue&#x2A; growth and 11%-13% segment EBITDA margin.

GE Vernova Reaffirms FY25 Revenue Guidance Of $36B-$37B Vs. $36.88B Estimate

Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) shares are trading higher premarket on Wednesday.
On Tuesday, the company disclosed new AI agents and generative AI features in Oracle Fusion Cloud Sales to enhance sales <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n43118973/oracle-ai-agents-help-sales-teams-create-more-meaningful-customer-connections" rel="noreferrer noopener">engagement and streamline processes</a>.
These AI capabilities, integrated with Oracle Fusion Cloud Customer Experience (CX), would help sales teams streamline communication, maintain up-to-date records, and build stronger customer relationships.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43111153/nvidia-and-ai-stock-rises-as-trump-announces-500-billion-stargate-ai-infrastructure-venture" rel="noreferrer noopener">Nvidia, AI Stocks Rise As Trump Announces $500 Billion Stargate AI Infrastructure Venture</a>
The AI-powered engagement agent generates optimized emails, while the records agent automates activity summaries and data entry.
Rob Tarkoff, executive vice president and general manager, Oracle Cloud CX said, &#8220;The new AI agents and generative AI capabilities within Oracle Cloud Sales eliminate many of these rigid and time-consuming tasks, which enables sales teams to boost productivity and create more impactful connections with customers.&#8221;
Gartner predicts that by 2026, B2B sales teams using generative AI will cut prospecting and customer-meeting prep time by over 50%.
Yesterday, co-founder&nbsp;Larry Ellison unveiled plans for an artificial intelligence-driven cancer vaccine system <a target="_blank" href="https://www.benzinga.com/markets/equities/25/01/43118941/oracles-larry-ellison-says-cancer-vaccine-tailored-in-48-hours-could-soon-be-a-reality-as-trump-announces-500-billion-ai-investment" rel="noreferrer noopener">that could deliver personalized treatments within 48 hours</a>.
The announcement came as part of a broader $500 billion AI infrastructure initiative called Stargate, a joint venture between Oracle,&nbsp;OpenAI, and&nbsp;SoftBank Group. The project will&nbsp;establish massive data centers&nbsp;across the U.S., starting with a facility in Abilene, Texas.
Investors can gain exposure to the stock via&nbsp;iShares Expanded Tech-Software Sector ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/IGV#BATS">IGV</a>) and FT Vest Technology Dividend Target Income ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/TDVI#BATS">TDVI</a>).
Price Action: ORCL shares are up 9% at $188.10 premarket at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/43119814/google-parent-owned-startup-to-launch-ai-designed-drug-trials-by-year-end-partnering-with-eli-lilly-and-novartis-to-tackle-major-diseases" target="_blank" rel="noreferrer noopener">Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases</a></li>
</ul>
Photo via Shutterstock.

Equities

Large Cap

Tech

ORCL

TDVI

Oracle Unveils AI-Powered Sales Tools To Boost Customer Engagements: Details

Johnson & Johnson shares are trading higher after the company reported better-than-expected Q4 adjusted EPS and revenue.

Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) reported quarterly adjusted earnings of $1.20 per share which missed the analyst consensus estimate of $1.26 by 4.76 percent. This is a 17.81 percent decrease over earnings of $1.46 per share from the same period last year. The company reported quarterly sales of $825.00 million which missed the analyst consensus estimate of $837.57 million by 1.50 percent. This is a 5.50 percent increase over sales of $782.00 million the same period last year.

Comerica Q4 Adj $1.20 Misses $1.26 Estimate, Sales $825.00M Miss $837.57M Estimate

DELL

MSFT

NVDA

Shares of AI tech companies are trading higher after President Trump announced a $500 billion AI infrastructure investment called Project Stargate.

Stifel analyst James Condulis initiates coverage on Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy rating and announces Price Target of $80.

CYTK

Stifel Initiates Coverage On Cytokinetics with Buy Rating, Announces Price Target of $80

GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) reported quarterly earnings of $1.73 per share which missed the analyst consensus estimate of $2.55 by 32.16 percent. This is a 140.28 percent increase over earnings of $0.72 per share from the same period last year. The company reported quarterly sales of $10.59 billion which missed the analyst consensus estimate of $10.78 billion by 1.76 percent. This is a 8.51 percent increase over sales of $9.76 billion the same period last year.

GE Vernova Q4 2024 GAAP EPS $1.73 Misses $2.55 Estimate, Sales $10.59B Miss $10.78B Estimate

Full-year 2025 guidance:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">($ in Billions, except EPS)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">January 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Adjusted Operational Sales1,2,5
Change vs. Prior Year / Mid-point
</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2.0% – 3.0% / 2.5%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Operational Sales2,5 / Mid-point
Change vs. Prior Year / Mid-point
</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">
$90.9B – $91.7B / $91.3B
2.5% – 3.5% / 3.0%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Estimated Reported Sales3,5/ Mid-point
Change vs. Prior Year / Mid-point
</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">
$89.2B – $90.0B / $89.6B
0.5% – 1.5% / 1.0%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Adjusted Operational EPS (Diluted)2,4 / Mid-point
Change vs. Prior Year / Mid-point
</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">
$10.75 – $10.95 / $10.85
7.7% – 9.7% / 8.7%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Adjusted EPS (Diluted)3,4 / Mid-point
Change vs. Prior Year / Mid-point
</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">
$10.50 – $10.70 / $10.60
5.2% – 7.2% / 6.2%
</td>
</tr>
</tbody>
</table>
</figure>

Biotech

Health Care

Johnson & Johnson Expects 2025 Adjusted EPS Of $10.75–$10.95 Versus Consensus Of $10.59

William Blair analyst Max Smock downgrades Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) from Outperform to Market Perform.

Downgrades

William Blair Downgrades Charles River to Market Perform

Stifel analyst James Condulis initiates coverage on Edgewise Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) with a Hold rating and announces Price Target of $30.

EWTX

Stifel Initiates Coverage On Edgewise Therapeutics with Hold Rating, Announces Price Target of $30

TransAtlantic Capital

Comments

TransAtlantic Capital

TransAtlantic Capital (TACI) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga